talacotuzumab
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 4, 2015 (NCT02472145)
Timeline
Indications
Mechanism of action
- Interleukin-3 receptor subunit alphaBINDING AGENT
Interleukin-3 receptor subunit alpha binding agent
- Interleukin-3 receptor subunit alphaINHIBITOR
IL3RA inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297837 ↗
Also known as
- jnj-56022473
- talacotuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03011034 | Phase 2 | Feb 14, 2017 | Johnson and Johnson |
| NCT02920424 | Phase 1 | Oct 1, 2016 | Johnson and Johnson |
| NCT02992860 | Phase 2 | Jul 1, 2016 | GWT-TUD GmbH, Paris Diderot University |
| NCT02472145 | Phase 3 | Aug 4, 2015 | Johnson and Johnson |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 3 | 3 | 3 | 2015 |
| GWT-TUD GmbH | For profit | 1 | 1 | 1 | 2016 |
| Paris Diderot University | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1